Please login to the form below

Not currently logged in
Email:
Password:

MannKind

This page shows the latest MannKind news and features for those working in and with pharma, biotech and healthcare.

Sanofi abandons inhaled insulin pact with Mannkind

Sanofi abandons inhaled insulin pact with Mannkind

Sanofi has handed back rights to inhaled insulin drug Afrezza to Mannkind, less than a year after its launch, after the diabetes treatment saw underwhelming sales. ... In a statement, Mannkind said it will "promptly commence transition discussions" with

Latest news

  • AstraZeneca and its diabetes plans AstraZeneca and its diabetes plans

    A good example of this is MannKind and Sanofi's Afrezza (insulin human), the world's first inhaled that made it to market.

  • Sanofi launches inhaled insulin in US Sanofi launches inhaled insulin in US

    Partners with MannKind on only diabetes treatment of its kind.  . The device Afrezza will be distributed in. Sanofi has launched what will be the only inhaled insulin available to treat people ... The company is working with the drug's inventor MannKind

  • Sanofi cuts $925m deal for MannKind's inhaled insulin Sanofi cuts $925m deal for MannKind's inhaled insulin

    French company bolsters diabetes business with Afrezza collaboration. This inhaler is designed to be used with Mannkind's inhaled insulin Afrezza. ... MannKind's search for a partner for its recently approved inhaled insulin therapy Afrezza has ended

  • Third time lucky as MannKind's inhaled insulin is approved Third time lucky as MannKind's inhaled insulin is approved

    US FDA backs new diabetes treatment Afrezza. An inhaled formulation of insulin for diabetes could be back on the market shortly after the US FDA approved MannKind's Affrezza. ... MannKind's formulation exerts its effects more quickly than injections, so

  • MannKind's inhaled insulin backed for US approval MannKind's inhaled insulin backed for US approval

    MannKind's inhaled diabetes therapy Afrezza won the support of an FDA advisory committee yesterday, taking the product to the brink of approval. ... Several have been proffering turnover predictions in the region of $500m a year within five years, while

More from news
Approximately 7 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    It was a big news month for Sanofi, also in the news for terminating its licensing deal with MannKind for Afrezza (inhaled insulin). ... 150. MannKind/ Receptor Life Sciences. Licence, collaboration. Multiple inhaled therapeutic products for conditions

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    The only alternative to injections of the hormone at the moment is Mannkind's inhaled insulin Afrezza - partnered with Sanofi - which has not gained much momentum yet in the marketplace with

  • Going the distance Going the distance

    But it didn't have an easy road to market, with its developer Mannkind having to wait until its third marketing application before receiving approval from the FDA.

  • Pharma deals during August 2014 Pharma deals during August 2014

    The long process involved three FDA approval attempts and MannKind will need to exercise patience with the promised profit share down the line. ... As well as the $150m upfront MannKind will receive up to $775m in milestones and a 35% profit share on

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    8, 300. MannKind/ Sanofi. Licence. Afrezza (human insulin) Rapid-Acting Inhaled Insulin (approved US).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • MannKind boosts its senior management team MannKind boosts its senior management team

    Matthew Pfeffer becomes chief executive officer. California-based MannKind has appointed Matthew Pfeffer as its chief executive officer to replace Alfred Mann, who had held the role ad interim since November. ... Pfeffer will continue to serve as Mannkind

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics